FrancophonIA/ELRC3.0 huggingface dataset:
English: • The user group of <invented name> is likely to include patients that may have an inherently increased cardiovascular risk such as that associated with polycystic ovarian syndrome.
Maltese: • Il-grupp ta' utenti ta' <isem ivvintat> huwa probabbli li jinkludi pazjenti li jista' jkollhom riskju kardjovaskulari miżjud minnhom infushom bħal dak assoċjat ma' sindrome poliċistiku tal-ovarji.
English: • Extremely rarely, thrombosis has been reported to occur in other blood vessels, e.g. hepatic, mesenteric, renal, cerebral or retinal veins and arteries, in hormonal contraceptive users.
Maltese: • Rari ħafna, f'utenti ta' kontraċettivi ormonali, trombożi kienet irrappurtata li seħħet f'kanali taddemm oħra, eż. vini u arterji epatiċi, mesenteriċi, renali, ċerebrali jew retinali.
English: A blood clot in an artery can cause serious problems.
Maltese: Embolu tad-demm f'arterja jista' jikkawża problemi serji.
English: Stop taking tablets and contact your doctor immediately if you notice possible signs of a blood clot.
Maltese: Waqqaf il-pilloli u ikkuntattja lit-tabib tiegħek immedjatament jekk tinnota sinjali possibbli ta' embolu tad-demm.
English: Blood clots (thrombosis)
Maltese: FULJETT TA' TAGĦRIF
English: 23 September 2010 EMA/584655/2010 EMEA/H/C/001191
Maltese: EMA/584655/2010
English: The application was withdrawn at ‘day 180'.
Maltese: L-applikazzjoni ġiet irtirata wara ‘l-jum 180'.
English: Withdrawal of the marketing authorisation application for Rasival (aliskiren / valsartan) EMA/584655/2010
Maltese: Irtirar tal-applikazzjoni għat-tqegħid fis-suq għal Rasival (aliskiren / valsartan) EMA/584655/2010
English: What is Rasival?
Maltese: X'inhu Rasival?
English: Rasival is a medicine that contains the active substances aliskiren and valsartan.
Maltese: Rasival huwa mediċina li fiha s-sustanzi attivi aliskiren u valsartan.
English: Withdrawal of the marketing authorisation application for Rasival (aliskiren / valsartan)
Maltese: Irtirar tal-applikazzjoni għat-tqegħid fis-suq għal Rasival (aliskiren / valsartan)
English: This means that the CHMP had evaluated the documentation provided by the company and formulated a list of questions.
Maltese: Dan ifisser li s-CHMP ivvaluta d-dokumentazzjoni pprovduta mill-kumpanija u fformula lista ta' mistoqsijiet.
English: On 15 September 2010, Novartis Europharm Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Rasival, for the treatment of essential hypertension in adults whose blood pressure is already adequately controlled with a combination of aliskiren and valsartan taken separately.
Maltese: Fil-15 ta' Settembru 2010, Novartis Europharm Limited innotifikat uffiċjalment lill-Kumitat għallProdotti Mediċinali għall-Użu mill-Bniedem (CHMP) li tixtieq tirtira l-applikazzjoni tagħha għal awtorizzazzjoni għat-tqegħid fis-suq għal Rasival, li jintuża għat-trattament ta' pressjoni għolja essenzjali f'adulti li l-pressjoni tad-demm tagħhom diġà tkun ikkontrollata b'mod adegwat permezz ta' taħlita ta' aliskiren u valsartan meħudin separatament.
English: In addition, one main study was carried out in around 1,200 patients with essential hypertension.
Maltese: Barra dan, sar studju ewlieni wieħed f'madwar 1,200 pazjent bi pressjoni għolja essenzjali.
English: What was Rasival expected to be used for?
Maltese: Għal xiex kien mistenni jintuża Rasival?
English: The two active substances in Rasival are anti-hypertensive medicines that are already in use in the European Union (EU).
Maltese: Iż-żewġ sustanzi attivi f'Rasival huma mediċini kontra l-pressjoni għolja li diġà jintużaw fl-Unjoni Ewropea (UE).
English: Rasival was expected to be used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of aliskiren and valsartan taken separately.
Maltese: Rasival kien mistenni jintuża biex tiġi trattata l-pressjoni għolja essenzjali (pressjoni għolja tad-demm) f'adulti li l-pressjoni tad-demm tagħhom diġà tkun ikkontrollata b'mod adegwat permezz ta' taħlita ta' aliskiren u valsartan meħudin separatament.
English: How is Rasival expected to work?
Maltese: Kif kien mistenni jaħdem Rasival?
English: Aliskiren reduces the production of the angiotensin II (a hormone that narrows blood vessels), while valsartan blocks the receptors to which angiotensin II normally attaches.
Maltese: Aliskiren inaqqas il-produzzjoni ta' angiotensin II (ormon li jdejjaq il-vini tad-demm), filwaqt li valsartan jimblokka r-riċetturi li normalment teħel magħhom angiotensin II. Billi jimblokka l-attività ta' angiotensin II, Rasival jaġixxi biex iwessa' l-vini tad-demm u għalhekk inaqqas il-pressjoni tad-demm.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Rasival could not have been approved for the treatment of essential hypertension.
Maltese: Skont ir-reviżjoni tad-dejta u t-tweġiba tal-kumpanija għall-lista ta' mistoqsijiet tas-CHMP, fiż-żmien tal-irtirar, is-CHMP kellu xi tħassib u kien tal-fehma proviżorja li Ravisal ma kellux ikun approvat għattrattament tal-pressjoni għolja.
English: The letter from the company notifying the Agency of the withdrawal of the application is available under the tab ‘All documents'.
Maltese: L-ittra mill-kumpanija li tgħarraf lill-Aġenzija dwar l-irtirar tal-applikazzjoni tinsab taħt it-tab 'Iddokumenti kollha'.
English: The company informed the CHMP that there are no consequences for patients in clinical trials or compassionate use programmes, as there are no ongoing trials with Rasival.
Maltese: Qabel ma ġew studjati fuq il-bniedem l-effetti ta' Rasival għall-ewwel kienu ġew ittestjati fuq mudelli sperimentali.
English: The CHMP wanted further studies to be carried out on how Rasival behaved in the body, specifically after a patient has eaten food.
Maltese: Is-CHMP ried li jsiru aktar studji dwar l-imġiba ta' Ravisal fil-ġisem, b'mod speċifiku wara li pazjent ikun kiel l-ikel.
English: (N=969)
Maltese: (N=969) Rata (n)
English: Placebo (N=966)
Maltese: Plaċebo (N=966) Rata (n)
English: Hypromellose Macrogol 4000 Titanium dioxide (E171) Iron oxide yellow (E172)
Maltese: Titanium dioxide (E171) Iron oxide yellow (E172)
English: Daliresp 500 micrograms
Maltese: Daliresp 500 mikrogramma
English: Daliresp contains Lactose
Maltese: Daliresp fih lactose
English: Interaction studies with CYP1A2/3A4 inhibitor enoxacin and the CYP1A2/2C19/3A4 inhibitors cimetidine and fluvoxamine, resulted in increases of the total PDE4 inhibitory activity of 25%, 47% and 59%, respectively.
Maltese: Studji dwar interazzjonijiet ma' inibitur ta' CYP1A2/3A4 enoxacine u l-impedituri CYP1A2/2C19/3A4 cimetidine u fluvoxamine rriżultaw f'żidiet tal-attività inibitorja totali ta' PDE4 ta' 25%, 47% u 59%, rispettivament.
English: Date of first authorisation: 28 February 2011 Date of latest renewal: 24 April 2015
Maltese: Data tal-aħħar tiġdid: 24 ta' Apr 2015
English: What Daliresp contains - The active substance is roflumilast.
Maltese: X'fih Daliresp - Is-sustanza attiva hi roflumilast.
English: Ratio Roflumilast/Placebo
Maltese: Proporzjon Roflumilast/Placebo Valur-p ta' 2 naħat
English: Both roflumilast and roflumilast N-oxide have intrinsic phosphodiesterase 4 (PDE4) inhibitory activity.
Maltese: Kemm roflumilast kif ukoll roflumilast N-oxide għandhom attività intrinsika inibitorja ta' phosphodiesterase 4 (PDE4).
English: Daliresp contains the active substance roflumilast, which is an anti-inflammatory medicine called phosphodiesterase-4 inhibitor.
Maltese: Daliresp fih is-sustanza attiva roflumilast, li hi mediċina kontra l-infjammazzjoni msejħa inibitur ta' phosphodiesterase 4.
English: Daliresp is contraindicated in patients with moderate or severe liver impairment (Child-Pugh B or C).
Maltese: Daliresp hu kontraindikat f'pazjenti b'indeboliment moderat jew sever tal-wied (Child-Pugh B jew Ċ).
English: Daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.
Maltese: Daliresp hu indikat għal kura ta' manteniment ta' mard pulmonari ostruttiv kroniku (COPD) sever (FEV1 wara l-użu ta' bronkodilatur, inqas minn 50% ta' dak imbassar) assoċjat ma' bronkite kronika f'pazjenti adulti bi storja ta' aggravamenti frekwenti flimkien ma' kura bi bronkodilatur.
English: The observed adverse reactions for roflumilast in Study RO-2455404-RD were in line with those already included in section 4.8.
Maltese: Ir-reazzjonijiet avversi osservati għal roflumilast fi Studju RO-2455-404-RD kienu f'konformità ma' dawk li diġà ġew inklużi f'sezzjoni 4.8.
English: Daliresp 500 micrograms tablets roflumilast
Maltese: Daliresp 500 mikrogramma pilloli roflumilast
English: Other medicines and Daliresp
Maltese: Mediċini oħra u Daliresp
English: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Maltese: Sensittività eċċessiva għas-sustanza attiva jew għal kwalunkwe wieħed mill-eċċipjenti elenkati fis-sezzjoni 6.1).
English: Daliresp is to be used in addition to bronchodilators.
Maltese: Daliresp għandu jintuża flimkien ma' bronkodilaturi.
English: Children and adolescents Daliresp should not be used by children and adolescents under 18 years of age.
Maltese: Tfal u adolexxenti Daliresp m'għandux jintuża minn tfal u adolexxenti taħt l-età ta' 18-il sena.
English: Rescue medicinal products Daliresp is not indicated as rescue medicinal product for the relief of acute bronchospasms.
Maltese: Prodotti mediċinali ta' salvataġġ Daliresp mhuwiex indikat bħala prodott mediċinali ta' salvataġġ għas-solliev ta' bronkospażmi akuti.
English: Common side effects (may affect up to 1 in 10 people) - diarrhoea, nausea, stomach ache - weight decrease, decreased appetite - headache
Maltese: Effetti sekondarji komuni (jistgħu jaffettwaw sa persuna 1 f'10) - dijarea, tqalligħ, uġigħ fl-istonku - tnaqqis fil-piż, nuqqas t'aptit - uġigħ ta' ras
English: (LE) or progressive multifocal leukoencephalopathy (PML) - severe acute infectious diseases such as tuberculosis, or acute hepatitis - cancer (except basal-cell carcinoma, a slow-growing type of skin cancer) - or severe impairment of the heart function
Maltese: lupus erythematosus (LE), jew lewkoenċefalopatija multifokali progressiva (PML) - mard sever akut u infettiv bħal tuberkulosi, jew epatite akuta - kanċer (ħlief karċinoma taċ-ċelluli bażali, tip ta' kanċer tal-ġilda li jikber bil-mod) - jew indeboliment sever tal-funzjoni tal-qalb
English: Roflumilast 500 micrograms once daily significantly improved lung function compared to placebo, on average by 51 ml (pre-bronchodilator FEV1, p<0.0001), and by 53 ml (post-bronchodilator FEV1, p<0.0001).
Maltese: Kortikosterojdi li jinġibdu man-nifs intużaw fi 809 (61%) tal-pazjenti kkurati b'roflumilast, filwaqt li l-użu ta' LABAs u theophylline kien ipprojbit. roflumilast 500 mikrogramma darba kuljum tejjeb b'mod sinifikanti l-funzjoni tal-pulmun meta mqabbel mal-plaċebo, bħala medja b'51 ml (qabel l-użu ta' bronkodilatur FEV1, p<0.0001), u b'53 ml (wara l-użu ta' bronkodilatur FEV1, p<0.0001).
English: The pharmacokinetics of roflumilast 250 micrograms once-daily was tested in 16 patients with mild to moderate hepatic impairment classified as Child-Pugh A and B. In these patients, the total PDE4 inhibitory activity was increased by about 20% in patients with Child-Pugh A and about 90% in patients with Child-Pugh B. Simulations suggest dose proportionality between roflumilast 250 and 500 micrograms in patients with mild and moderate hepatic impairment.
Maltese: Il-farmakokinetika ta' roflumilast 250 mikrogramma mogħti darba kuljum kienet ittestjata f'16-il pazjenti li kellhom indeboliment tal-fwied minn ħafif sa moderat, ikklassifikati bħala Child-Pugh A u B.
English: Patients with moderate or severe hepatic impairment classified as Child-Pugh B or C must not take Daliresp (see section 4.3).
Maltese: Pazjenti b'indeboliment moderat jew sever epatiku ikklassifikat bħala Child-Pugh B jew Ċ m'għandhomx jieħdu Daliresp (ara sezzjoni 4.3).
English: The Marketing Authorisation Holder shall agree the content and format of the updated educational material with the national competent authority.
Maltese: Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq għandu jaqbel dwar il-kontenut u l-format tal-materjal edukattiv aġġornat mal-awtorità kompetenti nazzjonali.
English: The lack of experience in patients with HIV infection or active hepatitis, with severe immunological diseases (e.g.multiple sclerosis, lupus erythematosus, multifocal leukoencephalopathy) or treated with immunosuppressive therapy (other than short-term systemic corticosteroids) and that Dalirespshould not be initiated or should be stopped in these patients.
Maltese: In-nuqqas ta' esperjenza f'pazjenti b'infezzjoni bl-HIV jew epatite attiva, b'mard immunoloġiku sever (eż. sklerosi multipla, lupus eritematuż, lewkoenċefalopatija multifokali) jew li jkunu kkurati b'terapija immunosoppressiva (minbarra kortikosterojdi sistemiċi għal żmien qasir) u li Dalirespm'għandux jinbeda jew għandu jitwaqqaf f'dawn il-pazjenti.
English: The effect of Daliresp may be reduced if taken together with rifampicin (an antibiotic medicine) or with phenobarbital, carbamazepine or phenytoin (medicines usually prescribed for the treatment of epilepsy).
Maltese: L-effett ta' Daliresp jista' jitnaqqas jekk jittieħed flimkien ma' rifampicin (mediċina antibijotika) jew ma' phenobarbital, carbamazepine jew phenytoin (mediċini li normalment jingħataw riċetta għalihom għall-kura ta' epilessija).
English: Rare side effects (may affect up to 1 in 1,000 people) - male breast enlargement - decreased sense of taste - respiratory tract infections (excluding pneumonia) - bloody stools, constipation - elevation of liver or muscle enzymes (seen in blood tests) - wheals (urticaria).
Maltese: Effetti sekondarji rari (jistgħu jaffettwaw sa persuna 1 f'1000) - tkabbir tas-sider fl-irġiel - tħossok nervuż/a jew dipress/a; ħsibijiet u mġiba suwiċidali; tnaqqis fis-sens tat-togħma - infezzjonijiet tal-apparat respiratorju (li jeskludu l-pnewmonja) - ippurgar bid-demm, stitikezza - żieda tal-enzimi tal-fwied jew tal-muskoli (osservati fit-testijiet tad-demm) - nefħa fil-ġilda (urtikarja).
English: How to store Daliresp
Maltese: Jekk tieqaf tieħu Daliresp
English: OUTER CARTON FOR BLISTER
Maltese: F'analiżi miġbura minn studji
English: Analysis
Maltese: Deskrizzjoni
English: Daliresp is used for maintenance treatment of severe COPD in adults who in the past had frequent worsening of their COPD symptoms (so-called exacerbations) and who have chronic bronchitis.
Maltese: Daliresp jintuża bħala terapija ta' manteniment ta' COPD severa fl-adulti li fil-passat tagħhom kellhom sintomi li marru għall-agħar b'mod frekwenti (dawk li jissejħu taħrix) u li għandhom bronkite kronika..
English: Daliresp is not recommended if you have one or more of the following diseases: - severe immunological diseases such as HIV infection, multiple sclerosis (MS), lupus erythematosus
Maltese: Daliresp mhuwiex rakkomandat jekk għandek xi wieħed jew aktar tal-mard li ġej: - għal pazjenti li jkollhom mard immunoloġiku sever bħal infezzjoni bl-HIV, sklerosi multipla (MS),
English: Daliresp 500 micrograms film-coated tablets roflumilast
Maltese: Daliresp 500 mikrogramma pilloli miksija b'rita Roflumilast
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 November 2015 EMA/765377/2015 EMEA/H/C/003858
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 ta' Novembru 2015
English: The company that applied for authorisation is Marvel Lifesciences Ltd.
Maltese: Il-kumpanija li applikat għal awtorizzazzjoni hija Marvel Lifesciences Ltd.
English: Solumarv is a medicine that contains the active substance human insulin.
Maltese: Solumarv huwa mediċina li fiha s-sustanza attiva insulina umana.
English: The reference medicine for Solumarv in this application was Humulin S.
Maltese: Il-mediċina ta' referenza għal Solumarv f'din l-applikazzjoni kienet Humulin S.
English: Refusal of the marketing authorisation for Solumarv (insulin human)
Maltese: Rifjut tal-awtorizzazzjoni għat-tqegħid fis-suq għal Solumarv (insulina umana)
English: For more information on biosimilar medicines, see the question-and-answer document here.
Maltese: Għal aktar informazzjoni dwar il-mediċini bijosimili, ara d-dokument mistoqsijiet u tweġiba hawn.
English: Refusal of the marketing authorisation for Solumarv (insulin human) EMA/765377/2015
Maltese: EMA/861015/2015 EMEA/H/C/003858
English: The company presented results of studies in healthy people designed to show that Solumarv is similar to its reference medicine Humulin S in terms of biological activity and how the body handles the medicine.
Maltese: Il-kumpanija ppreżentat riżultati ta' studji ta' persuni b'saħħithom imfassla sabiex juru li Solumarv huma simili għall-mediċina ta' referenza Humulin S f'termini ta' attività bijoloġika u kif il-ġisem juża lmediċina.
English: Solumarv was intended as a replacement for the insulin made by the body.
Maltese: Solumarv kien maħsub li jintuża bħala sostitut għall-insulina prodotta mill-ġisem.
English: On 19 November 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of the marketing authorisation for the medicinal product Solumarv, intended for the treatment of diabetes.
Maltese: Fid-19 ta' Novembru 2015, il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) irrakkomanda r-rifjut tal-awtorizzazzjoni għat-tqegħid fis-suq għall-prodott mediċinali Solumarv maħsub għal kura tad-dijabete.
English: What was Solumarv expected to be used for?
Maltese: Għal xiex kien mistenni li jintuża Solumarv?
English: This means that it was intended to be similar to a biological medicine (the ‘reference medicine') already authorised in the European Union (EU).
Maltese: Dan ifisser li kien maħsub biex ikun simili għal mediċina bijoloġika (il-‘mediċina ta' referenza') li hija diġà awtorizzata fl-Unjoni Ewropea (UE).
English: The CHMP concluded that Solumarv could not be approved as a biosimilar of Humulin S and recommended that it be refused marketing authorisation.
Maltese: Is-CHMP ikkonkluda li Solumarv ma jistax jiġi approvat bħala bijosimili ta' Humulin S u rrakkomanda li l-awtorizzazzjoni għat-tqegħid fis-suq tiġi rrifjutata.
English: Two additional studies in patients with type 1 and type 2 diabetes compared the safety and effectiveness of Solumarv and Humulin S.
Maltese: Żewġ studji addizzjonali f'pazjenti bid-dijabete tat-tip 1 u t-tip 2 qabblu s-sigurtà u leffikaċja ta' Solumarv u Humulin S.
English: As such, it was not possible to show that Solumarv used in clinical studies was representative of batches intended for the market and that its quality was comparable to Humulin S's.
Maltese: Bħala tali, ma kienx possibbli li jintwera li s-Solumarv użat fi provi kliniċi kien rappreżentattiv tal-lottijiet maħsuba għas-suq u li l-kwalità tiegħu kien komparabbli ma' dak ta' Humulin S.
English: The company informed the CHMP that there are no clinical trials or compassionate use programmes affected by the Committee's opinion.
Maltese: Il-kumpanija għarrfet lis-CHMP li bħalissa m'hemm l-ebda prova klinika jew programm ta' użu b'kompassjoni affettwati mill-opinjoni tal-Kumitat.
English: Vet. Res. Comm. 9: 251-268
Maltese: Comm. 9: 251-268
English: 13721 PAROLA Finland
Maltese: 13721 PAROLA
English: Number of products
Maltese: Numru ta' prodotti
English: Av. Párroco Pablo Diez, 49 - 57 24010 - Leon
Maltese: Párroco Pablo Diez, 49 - 57 24010 - Leon
English: Slovak Republic CEVA Animal Health Slovakia, spol.
Maltese: CEVA Animal Health Slovakia, spol.
English: Ivermectin ”Virbac” Vet., injektionsvæske, opløsning
Maltese: Ivermectin ”Virbac” Vet., injektionsvæs ke, opløsning
English: Romivermectin B1 1%
Maltese: Romivermect in B1 1%
English: Merial Italia S.p.A. a Socio Unico, Via Vittor Pisani, 16
Maltese: a Socio Unico, Via Vittor Pisani, 16
English: Şoseaua de Centură, nr. 27-28, 077040 Chiajna, Ilfov Romania
Maltese: Şoseaua de Centură, nr. 27-28, 077040 Chiajna, Ilfov
English: 83 102 BRATISLAVA
Maltese: 83 102 BRATISLAVA Slovak Republic
English: Ceva-Phylaxia Oltóanyagtermelő Zrt.
Maltese: Ceva-Phylaxia Oltóanyagtermelő
English: United Kingdom Alstoe Ltd Sheriff Hutton Industrial Park Sheriff Hutton
Maltese: Sheriff Hutton Industrial Park Sheriff Hutton
English: 3., 1093 Budapest Hungary
Maltese: II. 3., 1093 Budapest Hungary
English: Veterina Polska Sp. Zo.o.
Maltese: Veterina Polska Sp.
English: The Netherlands Dopharma Research B.V. Zalmweg 24
Maltese: Dopharma Research B.V. Zalmweg 24
English: Scanvet Eläinlääkkeet Oy PL 27
Maltese: Il-Finlandja Scanvet Eläinlääkkeet Oy PL 27
English: VETERINA Plus d.o.o.,Dunajska 1000 Ljubljana,
Maltese: Is-Slovenja VETERINA Plus d.o.o.,Dunajska 51, 1000 Ljubljana,
English: The numbering of the formulation groups is arbitrary.
Maltese: In-numerazzjoni tal-gruppi tal-formulazzjonijiet hija arbitrarja.
English: Przedsiębiorstwo Wielobranżowe Vet Agro Sp. z o.o.
Maltese: Przedsiębiorstwo Wielobranżowe Vet Agro Sp. z o.o. ul.
English: Alfasan International B.V., P.O.
Maltese: Il-Bulgarija Alfasan International B.V., P.O.
English: VIRBAMEC Soluzione iniettabile
Maltese: Soluzione iniettabile
English: INTERVET ROMANIA S.R.L.
Maltese: Ir-Rumanija INTERVET ROMANIA S.R.L.
English: Kiszkowska 9 62-200 Gniezno Poland
Maltese: Kiszkowska 9 62-200
English: Such an effect has been shown in experimental studies performed by a number of different groups (Lo et al., 19853; Wicks et al., 19934; Lifschitz et al. 19995, Lifschitz et al., 20046).
Maltese: Wicks et al., 19934; Lifschitz et al. 19995, Lifschitz et al., 20046).
English: Spyros Stavrinides Chemicals Ltd 28 Stasinou Avenue, 1060 Nicosia,
Maltese: Spyros Stavrinides Chemicals Ltd 28 Stasinou Avenue, 1060
English: Intervet International B.V. Wim de Korvrstraat 35, 5831 AA, Boxmeer, The Netherlands
Maltese: Wim de Korvrstraat 35, 5831 AA, Boxmeer,
English: 949 01 Nitra
Maltese: 949 01 Nitra Slovak Republic
English: Bayer Hungária Ltd. H-1123 Budapest Alkotás u. 50.
Maltese: H-1123 Budapest Alkotás u. 50.
English: HEMOFARM - HEMOVET Beogradski Put BB Vrsac
Maltese: Ir-Rumanija HEMOFARM - HEMOVET Beogradski Put BB
English: Mogilska 80, 31546 Krakow Poland
Maltese: Mogilska 80, 31546
English: http://www.emea.europa.eu/pdfs/vet/swp/054203en.pdf
Maltese: rtirar http://www.emea.europa.eu/pdfs/vet/swp/003695en.pdf
English: ad us. vet.
Maltese: Virbamec inj. ad us. vet.
English: Czech Republic Bioveta a.s., Komenského 212
Maltese: Ir-Rumanija Bioveta a.s., Komenského 212
English: Formulation Group
Maltese: Grupp ta' formulazzjoni
English: Merial Norden A/S Mileparken 20 E 2740 Skovlunde Denmark
Maltese: Id-Danimarka Merial Norden A/S Mileparken 20 E
English: 40064 Ozzano Emilia (Bologna) Italy
Maltese: Ozzano Emilia (Bologna)
English: PASTEUR - Filiala Filipeşti Str. Principală, nr. 944, Filipeştii de Pădure,
Maltese: Principală, nr. 944, Filipeştii de Pădure, Jud.
English: 1991 JL Velserbroek The Netherlands
Maltese: Kleermakerstraat 10 1991 JL Velserbroek The Netherlands
English: a.u.v.
Maltese: B.V.
English: Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, Co. Galway, Ireland
Maltese: Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, Co.
English: Slovak Republic Pharmagal spol.s.r.o.
Maltese: Pharmagal spol.s.r.o.
English: Agri- Biovet Sp. z o.o.
Maltese: Agri- Biovet Sp. z o.o. ul.
English: Using the alternative approach and applying safety span of 10% a withdrawal period of 66 days was derived.
Maltese: Bl-użu tal-approċċ alternattiv u bl-applikazzjoni ta' perjodu ta' sigurtà ta' 10% irriżulta perjodu ta' rtirar ta' 66 jum.
English: Gran Vía Carlos III, 98 - 7ºth floor.
Maltese: Gran Vía Carlos III, 98 - 7ºth floor. 08028 Barcelona,
English: Ivomec 10 mg/ml Injektionssuspensi on für Rinder, Schafe und Schweine
Maltese: Ivomec 10 mg/ml Injektionssus pension für Rinder, Schafe und Schweine